Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
American Journal of Physiology. Heart and Circulatory Physiology
|
June 10, 2015
Chronic endurance exercise affects paracrine action of CD31+ and CD34+ cells on endothelial tube formation
Rian Q Landers-Ramos, Ryan M Sapp, Nathan T Jenkins, et al.
The Journal of Physiology
|
February 4, 2003
Alterations in slow-twitch muscle phenotype in transgenic mice overexpressing the Ca2+ buffering protein parvalbumin
Eva R Chin, Robert W Grange, Francois Viau, et al.
Acta Neuropathologica Communications
|
March 24, 2017
Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis
David R Amici, Iago Pinal-Fernandez, Davi A G Mázala, et al.
Mayo Clinic Proceedings
|
February 4, 2014
Exercise biology and medicine: innovative research to improve global health
Marcas M Bamman, Dan M Cooper, Frank W Booth, et al.
American Journal of Physiology. Cell Physiology
|
June 3, 2005
Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction
Lindsay M Angus, Joe V Chakkalakal, Alexandre Méjat, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 30, 2016
Investigating the extremes of the continuum of paracrine functions in CD34-/CD31+ CACs across diverse populations
Rian Q Landers-Ramos, Ryan M Sapp, Emily VandeWater, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 17, 2003
Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling
Joe V Chakkalakal, Mark A Stocksley, Mary-Ann Harrison, et al.
Journal of Medicinal Chemistry
|
October 4, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Chihyuan Chuang, Scott Collibee, Luke Ashcraft, et al.
Nature Cardiovascular Research
|
August 28, 2024
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
James J Hartman, Darren T Hwee, Julien Robert-Paganin, et al.
Science Translational Medicine
|
November 1, 2016
NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation
Dongryeol Ryu, Hongbo Zhang, Eduardo R Ropelle, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
American Journal of Physiology. Heart and Circulatory Physiology
|
June 10, 2015
Chronic endurance exercise affects paracrine action of CD31+ and CD34+ cells on endothelial tube formation
Rian Q Landers-Ramos, Ryan M Sapp, Nathan T Jenkins, et al.
The Journal of Physiology
|
February 4, 2003
Alterations in slow-twitch muscle phenotype in transgenic mice overexpressing the Ca2+ buffering protein parvalbumin
Eva R Chin, Robert W Grange, Francois Viau, et al.
Acta Neuropathologica Communications
|
March 24, 2017
Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis
David R Amici, Iago Pinal-Fernandez, Davi A G Mázala, et al.
Mayo Clinic Proceedings
|
February 4, 2014
Exercise biology and medicine: innovative research to improve global health
Marcas M Bamman, Dan M Cooper, Frank W Booth, et al.
American Journal of Physiology. Cell Physiology
|
June 3, 2005
Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction
Lindsay M Angus, Joe V Chakkalakal, Alexandre Méjat, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 30, 2016
Investigating the extremes of the continuum of paracrine functions in CD34-/CD31+ CACs across diverse populations
Rian Q Landers-Ramos, Ryan M Sapp, Emily VandeWater, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 17, 2003
Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling
Joe V Chakkalakal, Mark A Stocksley, Mary-Ann Harrison, et al.
Journal of Medicinal Chemistry
|
October 4, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Chihyuan Chuang, Scott Collibee, Luke Ashcraft, et al.
Nature Cardiovascular Research
|
August 28, 2024
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
James J Hartman, Darren T Hwee, Julien Robert-Paganin, et al.
Science Translational Medicine
|
November 1, 2016
NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation
Dongryeol Ryu, Hongbo Zhang, Eduardo R Ropelle, et al.
Page
of 4